Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range.
Relative Strength Index Analysis Today
Relative Strength Index measures the speed and magnitude of recent price changes on a 0-to-100 scale, showing whether recent trading has leaned stronger or weaker within its range. The current Relative Strength Index for Galmed Pharmaceuticals is 47.98. This reading indicates consistent price behavior relative to the prior session.
On May 08 2026 Galmed Pharmaceuticals was traded for 0.61 at the closing time. The top price for the day was 0.66 and the lowest listed price was 0.61 . The trading volume for the day was 109.7 K. The trading history from May 8, 2026 remained within defined bounds. The net trading delta against the current closing price is 3.28% .
Readings near the middle of the range usually indicate balanced price behavior, while higher or lower readings reflect stronger directional pressure.
Related Price-Series Methods for Galmed Pharmaceuticals
These methods summarize the same price history through smoothing, range, and momentum calculations. Reviewing them alongside Relative Strength Index helps compare stable sessions with periods of wider price movement in Galmed Pharmaceuticals.
These firms work in a similar space as Galmed Pharmaceuticals within the Health Care space and serve as useful points for comparison. Market cap and total value checks frame Galmed Pharmaceuticals' size within the competitive field. Identifying peers that steadily beat or lag Galmed Pharmaceuticals across many periods highlights durable competitive gaps.
Rate of Change and Momentum readings for Galmed Pharmaceuticals measure the velocity of recent price moves rather than direction alone. These indicators add context to how recent sessions in Galmed Pharmaceuticals have behaved.
Standard deviation and variance for Galmed Pharmaceuticals measure total price dispersion, while semi-deviation isolates only the downside moves. Higher variance relative to sector peers signals that Galmed Pharmaceuticals' price path has been less predictable over the measured period.
Please note, the risk measures we provide can be used independently or collectively to perform a risk assessment. When comparing two potential investments, we recommend comparing similar equities with homogenous growth potential and valuation from related markets to determine which investment holds the most risk.
Galmed Pharmaceuticals Short Properties
Short sentiment tied to Galmed Pharmaceuticals matters because heavier bearish pressure can change how quickly future price expectations become unstable. The practical goal is to identify when the balance between long and short participation may be changing the quality of the setup.
Common Stock Shares Outstanding
4.31 million
Cash And Short Term Investments
18.16 million
More Resources for Galmed Stock Analysis
A broader look at Galmed Pharmaceuticals comes from its financial reports and historical data. Highlighted below are reports that provide context for Galmed Pharmaceuticals Stock: